| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8963750 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 14 Pages |
Abstract
Omalizumab use for asthma has been gradually decreasing following a peak shortly after its market availability. Many omalizumab users have low or very low adherence rates for ICSs and/or ICS-LABA in the 12 months before omalizumab initiation.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Molly M. PhD, Nilay D. PhD, Pinar PhD, Joseph S. MD, MHS, Matthew A. MD,